GRAFTCAGE ACX

K053080 · Osteotech, Inc. · MQP · Dec 1, 2005 · Orthopedic

Device Facts

Record IDK053080
Device NameGRAFTCAGE ACX
ApplicantOsteotech, Inc.
Product CodeMQP · Orthopedic
Decision DateDec 1, 2005
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3060
Device ClassClass 2
AttributesTherapeutic

Intended Use

The GraftCage™ ACX is a vertebral body replacement device intended to replace a collapsed, damaged, or unstable vertebral body in the thoracic or lumbar spine (TI-L5). The GraftCage™ ACX is indicated for a partial or total vertebrectomy for cases of tumor or trauma (i.e., fracture). The GraftCage™ ACX is intended to achieve anterior decompression of the spinal cord and neural tissues and to restore the height of a collapsed vertebral body. The GraftCage™ ACX is intended for use with supplemental internal spinal fixation systems that are cleared by FDA for use in the thoracic and lumbar spine. These systems include posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems. The use of bone grafting material with the GraftCage™ ACX is optional.

Device Story

GraftCage™ ACX is a vertebral body replacement (VBR) implant; rectangular, PEEK-OPTIMA polymer construction; features central/lateral fenestrations for bone graft material; superior/inferior ridges for migration resistance; tapered posterior aspect for insertion. Used in thoracic/lumbar spine surgery following vertebrectomy; implanted by surgeons using a dedicated threaded insertion tool. Device restores vertebral height and achieves anterior decompression. Requires supplemental internal fixation (pedicle screw/rod or plate systems). Benefits include structural support for collapsed/damaged vertebrae.

Clinical Evidence

Bench testing only. No clinical data provided.

Technological Characteristics

Material: PEEK-OPTIMA polymer. Form factor: Rectangular, lordotic or parallel configurations, tapered posterior. Features: Axial/lateral fenestrations for bone graft, superior/inferior ridges for fixation. Energy source: None (mechanical implant). Connectivity: None. Sterilization: Not specified.

Indications for Use

Indicated for patients requiring partial or total vertebrectomy in the thoracic or lumbar spine (T1-L5) due to tumor or trauma (fracture). Must be used with supplemental internal spinal fixation.

Regulatory Classification

Identification

A spinal intervertebral body fixation orthosis is a device intended to be implanted made of titanium. It consists of various vertebral plates that are punched into each of a series of vertebral bodies. An eye-type screw is inserted in a hole in the center of each of the plates. A braided cable is threaded through each eye-type screw. The cable is tightened with a tension device and it is fastened or crimped at each eye-type screw. The device is used to apply force to a series of vertebrae to correct “sway back,” scoliosis (lateral curvature of the spine), or other conditions.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ 2005 DEC 1 ## 510(k) Summary GraftCage™ ACX | October 28, 2005 | | | |----------------------|----------------------------------------------------|--| | Submitted By: | Osteotech, Inc. | | | Address: | 51 James Way<br>Eatontown, New Jersey 07724 | | | Telephone: | (800) 537-9842, Ext. 6324 | | | Contact Person: | Christopher Talbot<br>Director, Regulatory Affairs | | | Subject Device | | | | Trade Name: | GraftCage™ ACX | | | Common Name: | Vertebral Body Replacement Device | | | Classification Name: | Spinal Intervertebral Body Fixation Orthosis | | #### Device Description: The GraftCage™ ACX is a device designed to replace a thoracic or lumbar vertebral body and to support axial compression loads following vertebrectomy for the treatment of spinal tumors and in bases of spinal trauma/fracture. The GraftCage™ ACX is made from implantable PEEK-OPTIMA (polyetheretherketone) polymer. The GraftCage™ ACX is basically rectangular in shape. One central (axial) fenestration and one fenestration on each lateral aspect (on certain sizes) provide locations for the addition of bone grafting material. The superior and inferior aspects have ridges that resist expulsion and for migration after implantation. The device offers lordotic and non-lordotic i.e., parallel configurations. The posterior aspect of both design configurations is tapered, or bulleted, for ease of insertion. A single threaded hole at the posterior aspect interfaces with the insertion tool. The insertion tool is a shaft attached to a handle. The shaft has a threaded end that matches the threaded hole on the GraftCage™ ACX and allows the surgeon to hold the GraftCage™ ACX while implanting it into the patient. ## Intended Use: The GraftCage™ ACX is a vertebral body replacement device intended to replace a collapsed, damaged, or unstable vertebral body in the thoracic or lumbar spine (TI-L5). The GraftCage™ ACX is indicated for a partial or total vertebrectomy for cases of tumor or trauma (i.e., fracture). The GraftCage™ ACX is intended to achieve anterior decompression of the spinal cord and neural tissues and to restore the height of a collapsed vertebral body. 【 - 】 {1}------------------------------------------------ The GraftCage™ ACX is intended for use with supplemental internal spinal fixation systems that are cleared by FDA for use in the thoracic and lumbar spine. These systems include posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems. The use of bone grafting material with the GraftCage™ ACX is optional. ## Comparison to Predicate: The GraftCage™ ACX claims substantial equivalence to: - Osteotech, Inc. VBR, K012254 1) - DePuy AcroMed VBR System, K030833/K031635; 2) - Spinal Concepts Fortitude Vue Vertebral Body Replacement Device, K05100; and 3) - Implex Corporation Hedrocel Vertebral Body Replacement System, K010378. 4) This claim of substantial equivalence is intended to reflect FDA's definition of substantial equivalence as defined by 21 CFR Part 807, Subpart E and is not intended to reflect a claim of substantial equivalence in terms of intellectual property. The GraftCage™ ACX and the predicate devices have the same intended use and similar technological characteristics. Performance data demonstrates that the GraftCage™ ACX meets or exceeds functional requirements for a vertebral body replacement device. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three heads, representing the department's commitment to health, human services, and science. The eagle is surrounded by a circular border with the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES . USA" written around it. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 DEC 1 2005 Christopher Talbot Director Regulatory Affairs Osteotech, Inc. 51 James Way Eatontown, New Jersey 07724 Re: K053080 Trade/Device Name: GraftCage™ ACX Regulation Number: 21 CFR 888.3060 Regulation Name: Spinal intervertebral body fixation orthosis Regulatory Class: II Product Code: MQP Dated: November 1, 2005 Received: November 2, 2005 Dear Mr. Talbot: We have reviewed your Section 510(k) premarket notification of intent to market the device w one reviews. Jour cooleremined the device is substantially equivalent (for the indications for referenced in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it r your de hive t to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2-Christopher Talbot This letter will allow you to begin marketing your device as described in your Section 510(k) I mo lotet watification. The FDA finding of substantial equivalence of your device to a legally premaince notification - results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please 11 you don't e epice of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small general international and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, CM. N. Mikkelsen Mark N. Melkerson Acting Director Division of General, Restorative, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ 1053080 GraftCage™ ACX 510(k) Notification Osteotech, Inc. ## INDICATIONS FOR USE STATEMENT # 510(k) NUMBER (IF KNOWN): DEVICE NAME: GraftCage™ ACX ## INDICATIONS FOR USE: The GraftCage™ ACX is a vertebral body replacement device intended to replace a collapsed, damaged, or unstable vertebral body in the thoracic or lumbar spine (TI-L5). The GraftCage™ ACX is indicated for a partial or total vertebrectorny for cases of turnor or trauma (i.e., fracture). The GraftCage™ ACX is intended to achieve anterior decompression of the spinal cord and neural tissues and to restore the height of a collapsed vertebral body. The GraftCage™ ACX is intended for use with supplemental internal spinal fixation systems that are cleared by FDA for use in the thoracic and lumbar spine. These systems include posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems. The use of bone grafting material with the GraftCage™ ACX is optional. Prescription Use X (Per 21 CFR 801.109) OR Over-The-Counter-Use ### PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED. Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices | 510(k) Number | C053080 | |---------------|---------| |---------------|---------| C-1
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%